Harnessing the Power of Genomics and Proteomics

2003 ◽  
Vol 1 (1) ◽  
pp. 3-14
Keyword(s):  
Genomics And Proteomics

Hidden Markov Processes

2014 ◽  
Author(s):  
M. Vidyasagar
Keyword(s):  
Hidden Markov Models ◽  
Markov Processes ◽  
Viterbi Algorithm ◽  
Markov Models ◽  
Hidden Markov ◽  
Local Alignment ◽  
Biological Applications ◽  
Standard Material ◽  
Hidden Markov Processes ◽  
Genomics And Proteomics

This book explores important aspects of Markov and hidden Markov processes and the applications of these ideas to various problems in computational biology. It starts from first principles, so that no previous knowledge of probability is necessary. However, the work is rigorous and mathematical, making it useful to engineers and mathematicians, even those not interested in biological applications. A range of exercises is provided, including drills to familiarize the reader with concepts and more advanced problems that require deep thinking about the theory. Biological applications are taken from post-genomic biology, especially genomics and proteomics. The topics examined include standard material such as the Perron–Frobenius theorem, transient and recurrent states, hitting probabilities and hitting times, maximum likelihood estimation, the Viterbi algorithm, and the Baum–Welch algorithm. The book contains discussions of extremely useful topics not usually seen at the basic level, such as ergodicity of Markov processes, Markov Chain Monte Carlo (MCMC), information theory, and large deviation theory for both i.i.d and Markov processes. It also presents state-of-the-art realization theory for hidden Markov models. Among biological applications, it offers an in-depth look at the BLAST (Basic Local Alignment Search Technique) algorithm, including a comprehensive explanation of the underlying theory. Other applications such as profile hidden Markov models are also explored.

New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States

2013 ◽  
Vol 6 (2) ◽  
pp. 2009-2013
Author(s):  
D Samba Reddy
Keyword(s):  
Drug Approval ◽  
The United States ◽  
New Drugs ◽  
New Combination ◽  
Drug Status ◽  
Combination Drug ◽  
Human Cord Blood ◽  
Life Saving ◽  
Genomics And Proteomics ◽  
The Face

Thirty-nine (39) new drugs have been approved by the U.S. FDA in 2012, a record highest number of approvals since 1996. The record is a sign that pharma companies are poised to tap recent advances from genomics and proteomics. This list includes novel new drugs, known as new molecular entities (NMEs), biologics and new products. Many life-saving drugs are approved for marketing. The list includes a total of 10 drugs for cancer treatment, and nearly a quarter of those approved in 2012 had orphan drug status.  Among the breakthrough drugs approved in 2012 were ivacaftor (cystic fibrosis), vasmodegib (skin cancer), HPC-C (human cord blood product), ruxolitinib (myelofibrosis) and a new combination drug to treat HIV. In addition,  several unique products were approved for the treatment of macular degeneration, chronic weight management, overactive bladder, actinic keratosis, erectile dysfunction, glaucoma, respiratory distress syndrome, and COPD. The approval of 39 drugs in 2012 underscores a robust success rate and confirms that innovation is once again beginning to pay off. In the existing climate of reduced revenues in the face of generic competitions, the future and survival of big companies rests heavily on their unique niche products. It is apparent that big Pharma and a growing number of emerging Biotechs alike have focused their attention on developing new NMEs for rare diseases. In 2012, the length of the FDA’s review is shorter than agencies in other countries. Innovative models adopted for R&D strategies, communications, and new regulatory changes appear to shorten development timelines. Despite record drug approvals, there is bleak scope for blockbusters because most of these drugs have a limited market. The pipeline for blockbusters appears very low. However, there is unmet medical need for new drugs in autism, Alzheimer’s disease and epilepsy. Overall, the new drug approval list unveils unique and reemerging trends indicating that the pharma companies are poised for big growth from new brands approved for marketing for narrow-spectrum indications.    

Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics

2001 ◽  
Vol 2 (4) ◽  
pp. 399-415 ◽  
Author(s):  
Tuan Vo-Dinh ◽  
Minoo Askari
Keyword(s):  
Genomics And Proteomics

Analysis of Genomics and Proteomics Using DSP Techniques

2008 ◽  
Vol 55 (1) ◽  
pp. 370-378 ◽  
Author(s):  
K. Deergha Rao ◽  
M.N.S. Swamy
Keyword(s):  
Genomics And Proteomics

Contributions of functional genomics and proteomics to the study of immune responses in the Pacific white leg shrimp Litopenaeus vannamei

2009 ◽  
Vol 128 (1-3) ◽  
pp. 110-118 ◽  
Author(s):  
Javier Robalino ◽  
Ryan B. Carnegie ◽  
Nuala O‘Leary ◽  
Severine A. Ouvry-Patat ◽  
Enrique de la Vega ◽  
...  
Keyword(s):  
Immune Responses ◽  
Functional Genomics ◽  
Litopenaeus Vannamei ◽  
The Pacific ◽  
Genomics And Proteomics

scholarly journals Functional genomics and proteomics of the cellular osmotic stress response in `non-model' organisms

2007 ◽  
Vol 210 (9) ◽  
pp. 1593-1601 ◽  
Author(s):  
D. Kultz ◽  
D. Fiol ◽  
N. Valkova ◽  
S. Gomez-Jimenez ◽  
S. Y. Chan ◽  
...  
Keyword(s):  
Stress Response ◽  
Osmotic Stress ◽  
Functional Genomics ◽  
Model Organisms ◽  
Genomics And Proteomics ◽  
Osmotic Stress Response

Genomics and proteomics of heat acclimation

10.2741/s118 ◽  
2010 ◽  
Vol S2 (3) ◽  
pp. 1068-1080 ◽  
Author(s):  
Michal Horowitz
Keyword(s):  
Heat Acclimation ◽  
Genomics And Proteomics
Sign in / Sign up

Export Citation Format

Share Document